Fig. 1
Expression of TNFAIP8 in primary AML samples and cell lines. a Quantitative mRNA expression of TNFAIP8 by RT-qPCR in AML patient samples (n = 41) and controls (CTR, n = 17). b Quantitative mRNA expression of TNFAIP8 in patients with newly-diagnosed AML (n = 28), patients with relapsed/refractory AML (n = 13) and patients with complete remission (n = 19). Data are mean ± SD values calculated by Mann-Whitney U test. * P < 0.05; ** P < 0.01. c Representative immunoblotting analysis of TNFAIP8 in patients with newly-diagnosed AML (n = 8) and patients with relapsed/refractory AML (n = 6) relative to control (CTR, n = 1). d RT-qPCR and immunoblotting analysis of TNFAIP8 expression in acute myeloid leukemia cell lines relative to 293 T cell line (repeated three times). Data are mean ± SD values calculated by Mann-Whitney U test or one-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001 versus the 293 T group; # P < 0.05, ## P < 0.01 means the drug resistant cell line (K562/A02 or HL60/ADR) versus the sensitive cell line (K562 or HL60)